Scarica l'app Stockscreener
6.32
6.94%
0.41
Dopo l'orario di chiusura:
6.36
0.04
+0.63%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.91
Aprire:
$6.01
Volume 24 ore:
182.70K
Relative Volume:
0.95
Capitalizzazione di mercato:
$340.54M
Reddito:
-
Utile/perdita netta:
$-35.10M
Rapporto P/E:
-8.9633
EPS:
-0.7051
Flusso di cassa netto:
$-31.49M
1 W Prestazione:
+13.46%
1M Prestazione:
-0.16%
6M Prestazione:
-30.70%
1 anno Prestazione:
+55.67%
Intervallo 1D:
$5.92
$6.32
Intervallo di 1 settimana:
$5.501
$6.32
Portata 52W:
$3.475
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Nome
Diamedica Therapeutics Inc
Settore
Industria
Telefono
(763) 496-5454
Indirizzo
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.32 | 318.45M | 0 | -35.10M | -31.49M | -0.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-14 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-30 | Iniziato | TD Cowen | Buy |
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-06-22 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Iniziato | Oppenheimer | Outperform |
| 2021-02-17 | Iniziato | ROTH Capital | Buy |
| 2020-10-30 | Iniziato | Guggenheim | Buy |
| 2020-07-08 | Iniziato | Maxim Group | Buy |
| 2019-04-30 | Iniziato | Dougherty & Company | Buy |
| 2019-03-05 | Iniziato | Lake Street | Buy |
Mostra tutto
Diamedica Therapeutics Inc Borsa (DMAC) Ultime notizie
DiaMedica Shareholders Approve Governance, Compensation and Incentive Plan - The Globe and Mail
DiaMedica Therapeutics (NASDAQ: DMAC) investors approve directors, pay and 3.5M-share incentive plan boost - Stock Titan
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - BioSpace
DiaMedica stroke trial reaches 75% of interim analysis threshold By Investing.com - Investing.com South Africa
DiaMedica stroke trial reaches 75% of interim analysis threshold - Investing.com India
DiaMedica Therapeutics (DMAC) Advances in Pivotal Trial Enrollme - GuruFocus
DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment - marketscreener.com
Why Is DiaMedica Therapeutics Inc. (DMAC) Stock Down Today? - Meyka
TradingKey - TradingKey
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - BioSpace
DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
MSN Money - MSN
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2026 Earnings Call Transcript - insidermonkey.com
DiaMedica (DMAC) Q1 2026 Earnings Transcript - AOL.com
Why DiaMedica (DMAC) deserves a deeper look right now (Bearish Sentiment) 2026-05-08Social Investment Platform - newser.com
DiaMedica Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : DiaMedica Therapeutics Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
DiaMedica Therapeutics Q1 Earnings Call Highlights - Barchart.com
DiaMedica Therapeutics Inc. Q1 2026 Financial Results, Clinical Trial Updates, and Forward-Looking Statements - Minichart
Earnings call transcript: DiaMedica Therapeutics Q1 2026 results show R&D focus - Investing.com
DMAC: DM199 trials progress in preeclampsia and stroke, with strong cash position and key data ahead - TradingView
Diamedica Therapeutics Inc. (DMAC) Files Form 8-K with Financial Statements and Company Information for May 2026 - Minichart
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights - BioSpace
DiaMedica Therapeutics (NASDAQ:DMAC) Posts Wider Q1 Loss but Clinical Catalysts Fuel Stock Resilience - ChartMill
[10-Q] DiaMedica Therapeutics Inc. Quarterly Earnings Report - Stock Titan
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Higher R&D drives DiaMedica (NASDAQ: DMAC) wider Q1 2026 loss - Stock Titan
DiaMedica Therapeutics Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The National Law Review
DiaMedica Therapeutics (DMAC) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 - BioSpace
Top Wall Street forecasters revamp DiaMedica Therapeutics expectations ahead of Q4 earnings - MSN
DMAC Price Today: DiaMedica Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
DMAC DiaMedica Therapeutics Inc. reports narrower Q4 2025 loss than consensus forecasts, its stock rises modestly in today’s trading.Expert Market Insights - Cổng thông tin điện tử tỉnh Tây Ninh
Is DiaMedica (DMAC) stock worth committing funds to (Drifts Higher) 2026-04-22Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai
Diamedica Therapeutics Inc Azioni (DMAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Diamedica Therapeutics Inc Azioni (DMAC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| STAHLBERG JAN | 10% Owner |
Nov 21 '25 |
Buy |
7.41 |
208,872 |
1,547,574 |
8,712,390 |
| STAHLBERG JAN | 10% Owner |
Nov 18 '25 |
Buy |
6.75 |
182,882 |
1,234,618 |
8,134,740 |
| STAHLBERG JAN | 10% Owner |
Nov 17 '25 |
Buy |
6.52 |
187,393 |
1,221,165 |
7,951,858 |
| STAHLBERG JAN | 10% Owner |
Nov 20 '25 |
Buy |
7.41 |
128,426 |
951,213 |
8,503,518 |
| STAHLBERG JAN | 10% Owner |
Nov 25 '25 |
Buy |
8.57 |
73,099 |
626,817 |
8,825,742 |
| STAHLBERG JAN | 10% Owner |
Nov 24 '25 |
Buy |
7.89 |
40,253 |
317,721 |
8,752,643 |
| Parsons James T. | Director |
Nov 21 '25 |
Option Exercise |
2.20 |
12,000 |
26,400 |
87,854 |
| STAHLBERG JAN | 10% Owner |
Aug 25 '25 |
Buy |
6.00 |
338,265 |
2,029,252 |
7,654,045 |
| STAHLBERG JAN | 10% Owner |
Aug 13 '25 |
Buy |
5.91 |
293,601 |
1,734,918 |
7,058,066 |
| STAHLBERG JAN | 10% Owner |
Aug 14 '25 |
Buy |
5.99 |
70,414 |
421,921 |
7,128,480 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):